



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 33677-00000	SERIAL NO.: To Be Assigned
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT: Borodic et al.	
				FILING DATE: January 7, 2002	GROUP ART UNIT: To Be Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)					
			Acquadro, M. et al., Treatment of myofascial pain with botulinum A toxin. <i>Anesthesiology</i> , 3/94; 80(3): 705-6.		
			Anderson, R. et al., Blepharospasm past, present and future. <i>Ophthal Plast Reconstr Surgery</i> , 1998; 14(5): 305-17.		
			Barker, F., et al., The long term outcome of microvascular decompression for trigeminal neuralgia. <i>N Engl J Med</i> , 1996; 334: 1077-83.		
			Boghen, D., et al., Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. <i>Eur Neurol</i> , 1993; 33(3): 199-203.		
			Borodic, G., Myasthenic crisis after botulinum toxin. <i>Lancet</i> , 12/5/98; 352(9143): 1832.		
			Borodic, G., et al., Blepharospasm and its treatment, with emphasis on the use of botulinum A toxin. <i>Plast Reconstr Surg</i> , 3/89; 83(3): 546-54.		
			Borodic, G., et al., Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. <i>Plast Reconstr Surg</i> , 2/91; 87(2): 285-9.		
			Borodic, G., et al., Botulinum toxin therapy, immunologic resistance, and problems with available materials. <i>Neurology</i> , 1/96; 46(1): 26-29.		
			Buzzi, M., et al., 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. <i>Brain Res</i> , 6/26/92; 528(1-2): 127.		
			Buzzi, Mr., et al., Neurogenic model for migraine. <i>Cephalgia</i> , 1995; 15(4): 277-289.		
			Costigan, M. et al., Pain: molecular mechanisms. <i>The Journal of Pain, Supplement 1</i> , 2000; 1: 35-44.		
			Fields, H., Treatment of trigeminal neuralgia. <i>N Engl J Med</i> , 4/25/96; 334(17): 1125-6.		
			Johnson, E., Clostridial toxins as therapeutic agents: benefits of nature's most toxin proteins. <i>Annu Rev Microbiol</i> , 1999; 53: 551-75.		
			Mauriello, J., et al., Long term enhancement of botulinum toxin injections by upper eyelid surgery in 14 patients with facial dyskinesia. <i>Arch Otolaryngol Head Neck Surg</i> , 1999; 125(6): 627-31.		
			Poewe W., et al., Use of botulinum toxin in the treatment of cervical dystonia. <i>Baillieres Clin Neurol</i> , 4/93; 2(1): 179-85.		
		Sessle, B., Neural mechanisms of oral and facial pain. <i>Otolaryngologic Clinics of North America</i> , 1989; 22(6): 1059-72.			
EXAMINER			DATE CONSIDERED	11/16/03	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 33677-00000	SERIAL NO.: To Be Assigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Borodic et al.		
(Use several sheets if necessary)		FILING DATE: January 7, 2002	GROUP ART UNIT: To Be Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)				
		Siberstein, S. et al., Botulinum toxin type A as a migraine preventive treatment. <i>Headache</i> , 6/00; 40(6): 445-50.		Wilkinson, H., Trigeminal nerve peripheral branch phenol/glycerol injections for tic douloureux. <i>J Neurosurg</i> , 1999; 90(5): 828-32.
		Woolf, C., et al., Neuropathic pain: aetiology, symptoms, mechanisms, and management. <i>Lancet</i> , 1999; 353: 1959-64.		Woolf, C., et al., Transcriptional and posttranslational plasticity and the generation of inflammatory pain. <i>Proc. Natl. Acad. Sci.</i> 1999; 96: 7723-30.
		Yoon, K., et al. Long term outcome of percutaneous thermocoagulation for trigeminal neuralgia. <i>Anesthesia</i> , 08/99; 54(8): 803-808.		
EXAMINER			DATE CONSIDERED	11/16/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

JP932 U.S. PTO  
10/040830  
01/08/02